Co-Authors
This is a "connection" page, showing publications co-authored by PETER F THALL and STEVEN HSESHENG LIN.
Connection Strength
1.258
-
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022; 30:100514.
Score: 0.205
-
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
Score: 0.177
-
Bayesian Semiparametric Joint Regression Analysis of Recurrent Adverse Events and Survival in Esophageal Cancer Patients. Ann Appl Stat. 2019 Mar; 13(1):221-247.
Score: 0.169
-
Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017 06; 123(3):376-381.
Score: 0.148
-
Bayesian variable selection for a semi-competing risks model with three hazard functions. Comput Stat Data Anal. 2017 Aug; 112:170-185.
Score: 0.147
-
Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol. 2016 10; 121(1):70-74.
Score: 0.141
-
Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat. 2016 02; 65(2):273-297.
Score: 0.133
-
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85.
Score: 0.106
-
Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26.
Score: 0.032